精子发生相关基因SOX30基因在人前列腺癌组织中的表达及其临床意义  

Expression of spermatogenesis related gene SOX30 in human prostate cancer and its clinical significance

作　　者：王翰[1,2] 唐爱发[2] 

机构地区：[1]安徽医科大学,安徽合肥230031 [2]深圳市第二人民医院

出　　处：《中国男科学杂志》2017年第1期14-18,共5页Chinese Journal of Andrology

基　　金：深圳市科技计划项目(No.JSGG20160301162913683和JCYJ20130329104732074);深圳市高水平大学医学学科建设专项资金资助

摘　　要：目的研究SRY box containing gene 30(SOX30)基因在前列腺癌组织中表达情况,并且分析SOX30的表达与前列腺癌临床病理特征之间的相关性;并检测SOX30在前列腺癌细胞PC3、DU145、LNCaP以及正常人前列腺上皮细胞RWPE-1中的表达情况。方法采用免疫组织化学方法检测SOX30在前列腺癌组织中表达特点,采用逆转录实时定量聚合酶链式反应(RT-qPCR)和蛋白印迹法(Western Blotting)分析SOX30在PC3、DU145、LNCaP以及正常人前列腺上皮细胞RWPE-1中的表达情况,运用统计学方法分析SOX30蛋白表达量与前列腺癌临床病理特征之间的关系。结果在123例前列腺癌中,68例(55.28%)发生SOX30表达缺失,并且SOX30表达缺失与前列腺分期(P=0.001)、Gleason评分(P<0.001)有明显的相关性;与正常人前列腺上皮细胞RWPE-1相比,SOX30在PC3、DU145、LNCaP中表达明显降低。结论 SOX30可能是作为一个肿瘤抑制基因在前列腺癌的发生发展中起着重要作用。Objective To investigate the expression of SRY box containing gene 30 （SOX30） gene in prostate cancer tissues and analyze the relationship between SOX30 expression and clinicopathological characteristics; the expressions of SOX30 were detected in prostate cancer cells PC3, DU145, LNCaP and prostate epithelial cell RWPE-1; Methods Immunohistochemical was used to detect the expression of SOX30 in prostate cancer tissues; Reverse transcription quantitative polymerase chain reaction and Western blotting were used to analyze SOX30 expressions in prostate cancer cells PC3, DU145, LNCaP and prostate epithelial cells RWPE-1; The relationship between the expression ofSOX30 protein and clinicopathological features was analyzed by statistical methods. Results The expressions ofSOX30 were absent in 68 cases （55.28%）, and the expression of SOX30 was significantly correlated with the stage of prostate （P=0.001） and Gleason score （P〈0.001） in 123 cases of prostate cancer; the expressions of SOX30 in PC3, DU145 and LNCaP were significantly lower than that in RWPE-1. Conclusion SOX30 may be a tumor suppressor gene, which plays an important role in the development of prostate cancer.

关 键 词：前列腺肿瘤 免疫组织化学 基因 肿瘤抑制 

分 类 号：R737.25[医药卫生—肿瘤]